相似文献
1
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
Emerg Infect Dis. 2017 Oct;23(10):1718-21. doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.
2
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Int J Mol Sci. 2017 Feb 7;18(2):341. doi: 10.3390/ijms18020341.
3
Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?
Pediatr Infect Dis J. 2020 Jun;39(6):512-513. doi: 10.1097/INF.0000000000002601.
4
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13.
5
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Clin Infect Dis. 2019 Sep 13;69(7):1229-1231. doi: 10.1093/cid/ciz074.
6
Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Curr Opin Pulm Med. 2018 May;24(3):244-252. doi: 10.1097/MCP.0000000000000477.
7
Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman.
Emerg Infect Dis. 2017 Oct;23(10):1731-2. doi: 10.3201/eid2310.161398. Epub 2017 Oct 17.
8
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
BMC Health Serv Res. 2017 Mar 8;17(1):182. doi: 10.1186/s12913-017-2118-2.
9
Bedaquiline plus delamanid for XDR tuberculosis.
Lancet Infect Dis. 2016 Mar;16(3):294. doi: 10.1016/S1473-3099(16)00047-5.
10
Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature.
Medicine (Baltimore). 2016 Nov;95(46):e5347. doi: 10.1097/MD.0000000000005347.
引用本文的文献
1
Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) Drugs.
Pathogens. 2024 Nov 28;13(12):1045. doi: 10.3390/pathogens13121045.
2
A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.
J Clin Lab Anal. 2024 Aug;38(15-16):e25091. doi: 10.1002/jcla.25091.
3
Real-life use of delamanid: results from the European post-authorisation safety study.
IJTLD Open. 2024 Jun 1;1(6):274-278. doi: 10.5588/ijtldopen.24.0113. eCollection 2024 Jun.
4
Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India.
J Clin Tuberc Other Mycobact Dis. 2024 Apr 1;35:100433. doi: 10.1016/j.jctube.2024.100433. eCollection 2024 May.
5
Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.
Cell Mol Life Sci. 2023 Sep 14;80(10):291. doi: 10.1007/s00018-023-04914-5.
6
Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis.
Clin Infect Dis. 2022 Jun 29;76(3):e938-46. doi: 10.1093/cid/ciac528.
7
and Pulmonary Rehabilitation: From Novel Pharmacotherapeutic Approaches to Management of Post-Tuberculosis Sequelae.
J Pers Med. 2022 Apr 2;12(4):569. doi: 10.3390/jpm12040569.
8
Experiences of introducing new drugs for drug-resistant TB at the ALERT Hospital, Addis Ababa, Ethiopia, 2017-2019.
Public Health Action. 2021 Jun 21;11(2):50-52. doi: 10.5588/pha.20.0065.
9
Pneumonia caused by Mycobacterium tuberculosis.
Microbes Infect. 2020 Jul-Aug;22(6-7):278-284. doi: 10.1016/j.micinf.2020.05.020. Epub 2020 Jun 16.
10
New Drugs for the Treatment of Tuberculosis.
Clin Chest Med. 2019 Dec;40(4):811-827. doi: 10.1016/j.ccm.2019.08.001.
本文引用的文献
1
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Eur Respir J. 2017 May 21;49(5). doi: 10.1183/13993003.00387-2017. Print 2017 May.
2
Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.00146-2017. Print 2017 Mar.
3
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.02308-2016. Print 2017 Mar.
4
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
Eur Respir J. 2016 Nov;48(5):1527-1529. doi: 10.1183/13993003.01552-2016.
5
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
Eur Respir J. 2016 Nov;48(5):1526-1527. doi: 10.1183/13993003.01207-2016.
6
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
Eur Respir J. 2016 Sep;48(3):935-8. doi: 10.1183/13993003.00637-2016. Epub 2016 Jun 10.
7
Bedaquiline plus delamanid for XDR tuberculosis.
Lancet Infect Dis. 2016 Mar;16(3):294. doi: 10.1016/S1473-3099(16)00047-5.
8
Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence.
Eur Respir J. 2016 Feb;47(2):394-402. doi: 10.1183/13993003.01891-2015.
9
Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation.
Eur Respir J. 2014 Feb;43(2):554-65. doi: 10.1183/09031936.00079413. Epub 2013 Aug 15.
10
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.
Zotero 插件